Contact

 

Prof. Dr. med. Martin R. Berger
Phone: +49 6221 423310

E-mail: m.berger@dkfz.de

 

 

We focus on ...

 

metastasis resarch and anticancer drug development.

Toxicology and Chemotherapy Unit

DKFZ
 
 
 

Our group/department has:

  • Demonstrated that siRNA species enveloped into biodegradable nanoparticles can be used for successful treatment of osteolytic breast cancer metastasis (Elazar et al, Int. J. Cancer 2010)
  • Showed that the new ribosome-inactivating protein riproximin induces the unfolded protein response in human cancer cells (Horrix et al, Cell Mol. Life Sci 2011)
  • Showed that expression of the transcription factor HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma (Adwan et al. Br J Cancer 2011)
  • Demonstrated that erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma (Kapoor et al. Cancer Letters 2012)
  • Showed that the new ribosome-inactivating protein riproximin engages to certain sugar moieties as receptor and basis for its selective activity (Bayer et al. J Biol Chem 2012)
  • Members of the Unit have identified a new lead compound from a powder used by African healers that had shown activity against human prostate cancer. The active ingredient was identified as a type II ribosome-inactivating protein, which has since been termed riproximin. The mechanism of action of riproximin was identified as the unfolded protein response. In addition, the glyco-receptor of riproximin was identified, which will help to predict sensitivity to this agent.
  • Members of the Unit have assessed the importance of genes that are upregulated in pan¬cre¬atic cancer, namely osteopontin and osteonectin, and their transcription factors Runx2 and HoxC8. These genes also play a role in skeletal metastasis. Osteopontin and its close analog, bone sialoprotein, are involved in the genesis of these lesions. Knockdown of either of the two proteins re¬duced osteolytic skeletal and soft tissue lesions in vivo as did an antibody against BSP. This work was awarded with the first prize of the German Society for Senology, 2011.

2010 – 2013

  • Elazar V, Adwan H, Bäuerle T, Rohekar K, Golomb G, Berger MR.: Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialo-protein antisenses in rats with breast cancer bone metastasis. Int J Cancer. 126, 1749-1760 (2010)
  • Horrix C, Raviv Z, Flescher E, Voss C, Berger MR.: Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells. Cell Mol Life Sci. 68:1269–1281 (2011)
  • Adwan H., Zhivkova-Galunska M., Georges R., Eyol E., Kleeff J., Giese N.A., Friess H. Bergmann F., Berger M.R.: Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. Br J Cancer. 105: 288-95 (2011)
  • Kapoor V., Zaharieva M.M., Das S.N., Berger M.R.: Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Letters 319: 39-48 (2012)
  • Bayer H, Essig K, Stanzel S, Frank M, Gildersleeve JC, Berger MR, Voss C.: Evaluation of Riproximin binding properties reveals a novel mechanism for cellular targeting. J Biol Chem. 287(43):35873-86 (2012).
  • BMBF: Entwicklung eines rekombinanten therapeutischen Antikörpers zur Verhinderung der Bildung und zur Zerstörung vorhandener Knochenmetastasen. (2011-2014)
  • BMWI: Identifizierung und Charakterisierung der Bindung von Riproximin an Krebs-spezifische Glyco-Epitope. (2010-2012)
  • First prize of the German Society for Senology, 2011.
    Title: Silencing of Skeletal Metastasis-Associ¬ated Genes Impairs Migration of Breast Cancer Cells and Reduces Osteolytic Bone Lesions